Effectiveness of ovariohysterectomy on feline mammary fibroepithelial hyperplasia treatment

• Published in: Journal of feline medicine and surgery 2021-04, Vol.23 (4), p.351-356
• Main Authors: de Melo, Evelynne HM, Câmara, Diogo R, Notomi, Marcia K, Jabour, Flávia F, Garrido, Rita A, Nogueira, Alexandre CJ, Júnior, Jarbas CS, de Souza, Fernando W
• Format: Article
• Language: English
• Subjects: Animals; Cat Diseases - drug therapy; Cat Diseases - surgery; Cats; Female; Hyperplasia - veterinary; Hysterectomy - veterinary; Mammary Neoplasms, Animal - drug therapy; Mammary Neoplasms, Animal - surgery; Original; Ovariectomy - veterinary; Progestins
• ISSN: 1098-612X; 1532-2750; 1532-2750
• DOI: 10.1177/1098612X20950551

Objectives The aim of this study was to evaluate the effectiveness of ovariohysterectomy (OVH) on feline mammary fibroepithelial hyperplasia (FMFH) treatment, as well as the influence of previous injectable progestin on clinical signs and treatment of FMFH. Methods Seventy-nine female cats diagnosed with FMFH between 2014 and 2018 were included. The animals were distributed as follows: (1) treated only with OVH (TA) or OVH plus antiprogestin (TB); and (2) no administration (G1) or previous administration (G2) of injectable progestin before FMFH diagnosis. Data regarding clinical signs of FMFH, occurrence of persistent mammary growth after OVH, and time until complete remission of FMFH post-surgery were recorded and evaluated. Results Mastectomy was not performed in any cat during the study. TA was adopted in 71/79 (89.9%) cases, with 42/71 (59.2%) from G2 and 29/71 (40.8%) from G1. TB was adopted in 8/79 (10.1%) cats, all from G2. Total remission of FMFH was observed in 73/79 (92.4%) cats, with six animals from G2 having died (n = 6/79 [7.6%]). The time until complete remission of FMFH was higher (P